We are submitting the newspaper advertisements of the Audited financial results ( standalone & Consolidated ) for the quarter and financial year ended 31.03.2026 announced by the Company ....
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Ltd submitted newspaper advertisements of its audited standalone and consolidated financial results for Q4 and the financial year ended March 31, 2026. The results were approved by the Board of Directors on May 27, 2026, and published on May 29, 2026 in Financial Express (English) and Sanjayvani (Kannada). Standalone total income was approximately Rs 14,299 crore with net profit after tax of around Rs 512 crore for the full year. Consolidated total income was approximately Rs 49,427 crore with net profit after tax of around Rs 1,970 crore. The Board also declared a final dividend of Rs 2.5 per equity share (face value Rs 10) for FY2026, subject to shareholders' approval.
Bal Pharma reported audited annual results for FY2026 with a positive net profit trajectory on both standalone and consolidated bases. The declared dividend signals management confidence. Shareholders should review the detailed financial statements for full context.